Lessons Learned, Challenges, and Opportunities: The US Endocrine Disruptor Screening Program
Date: April 23-24, 2013
Location: North Carolina Biotechnology Center, Research Triangle Park, North Carolina
TUESDAY, APRIL 23, 2013
8:15 - 8:45 Welcome and Workshop Overview - Dr. Daland Juberg, Workshop Chair
“Why are we here?” - EDSP Workshop Organizing Committee
Presentation
8:45 - 8:50 Introduction to Session I - Dr. Susan Borghoff, Session Chair
8:50 - 9:30 Review of in vitro Assays - Validation Results and Methods for Improving in vitro Tier 1 Endocrine Disruption Screening Assays - – Dr. Colleen Toole, Ceetox Presentation
9:30 - 10:10 Review of in vivo Mammalian Assays - Challenges and Considerations for Conducting and Interpreting These Screening Assays - Dr. Leah Zorrilla, ILS, Inc.
10:10- 10:45 BREAK
10:45 - 11:30 Review of Non-mammalian Assays - Challenges and Potential Solutions for the Conduct and Interpretation of the Amphibian Metamorphosis Assay and the Fish Short Term Reproduction Assay - – Dr. Katherine Coady, The Dow Chemical Company
11:30 - 12:15 Panel Discussion and Audience Q&A : Dr. Ronald Biever, Smithers Viscient; Dr. Donald Stump, WIL Research; Dr. Kun (Sue) Yi, Syngenta Crop Protection
12:15 - 1:15 LUNCH
Session II - Practical Applications of Tier 1 Data
1:15 - 1:20 Introduction to Session II - Dr. Sue Marty, Session Chair
1:20 - 2:00 A Two-Tiered-Testing Decision Tree for Assays in the USEPA-EDSP Screening Battery: Using 15 years of experience to improve screening and testing for endocrine active chemicals - Dr. L. Earl Gray Jr., US Environmental Protection Agency
Presentation
2:00 - 2:40 Pulling it Together – Preparing for a Weight of Evidence Assessment on Endocrine Activity – Dr. Sue Marty, The Dow Chemical Co.
Presentation
2:40 - 3:15 BREAK
3:15 - 3:55 A Weight of Evidence Approach to Examine Endocrine Activity - Dr. Christopher Borgert, Applied Pharmacology & Toxicology, Inc.
3:55 - 4:45 Panel Discussion and Audience Q&A: Patricia Bishop, PETA; Dr. Kevin Crofton, US EPA; Dr. Ellen Mihaich, ER2 and Endocrine Policy Forum
4:45 - 5:00 Day One Wrap Up and Prelude to Day Two - Dr. Daland Juberg, Workshop Chair
WEDNESDAY, APRIL 24, 2013
Welcome Back and Poster Review
8:00 - 8:25 Welcome Back
Report from Poster Session, Dr. Richard Becker, American Chemistry Council
Session III- Considerations in the Future of Endocrine Testing
8:25 - 8:30 Introduction to Session III - Dr. Warren Casey, NIEHS; Dr. Jack Fowle, EPA, retired; and, Dr. Richard Becker, American Chemistry Council; Session Co-Chairs
8:30 - 9:00 EPA ToxCast HTS Assays and Prediction Models for Estrogen, Androgen, Thyroid and Steroidogenesis Pathways - Dr. David Dix, EPA NCCT
9:00 - 9:30 Tier 1 and Done: Developing in vitro Cell-based Assays of Endocrine Pathways Sufficient by Themselves for 21st Century Risk Assessment – Dr. Mel Andersen, The Hamner Institutes for Health Sciences
9:30 - 10:00 Mapping the Human Toxome by Systems Toxicology - Using ED as a Proof of Concept - Dr. Thomas Hartung, Center for Alternatives to Animal Testing, Johns Hopkins
10:00- 10:15 BREAK
10:15 - 10:35 The Future of Endocrine Screening: An Animal Welfare Perspective – Dr. Catherine Willett, Humane Society of the United States
10:35 - 10:55 Road Map for Building Scientific Confidence in HTP Assays- Dr. David Geter, Bayer CropScience, Presented by Dr. Lisa Ortego
Presentation
10:55 - 11:15 Designing the Next Generation of Sustainable Chemicals - Thaddeus Schug, NIEHS
11:15 - 12:00 Panel Discussion and Audience Q&A
12:00 - 12:45 LUNCH
Session IV - Participant Discussion
12:45 - 2:30 Dr. James C. Lamb, IV, Exponent, Inc., Opening Remarks
Dr. Michael Dourson, TERA, Facilitator
Closing Remarks
2:30 - 2:45 Dr. Daland Juberg, Workshop Chair
For more information, contact Jacqueline Patterson (patterson@tera.org or 513-542-7475)